日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment

两项 III 期临床试验评估了巴瑞替尼治疗重度斑秃成人患者的安全性,中位随访时间为 2.3 年,最长随访时间达 4 年。

King, Brett; Mostaghimi, Arash; Shimomura, Yutaka; Piraccini, Bianca Maria; Blume-Peytavi, Ulrike; Sontag, Angelina; Dutronc, Yves; Denning, Karen; Kolodsick, Jill; Lu, Xiaoyu; Srivastava, Ayush; Sinclair, Rodney

Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial

巴瑞替尼停药及重度斑秃患者再治疗:BRAVE-AA1随机临床试验

King, Brett; Ko, Justin; Kwon, Ohsang; Vañó-Galván, Sergio; Piraccini, Bianca Maria; Dutronc, Yves; Yu, Guanglei; Liu, Chunyuan; Somani, Najwa; Ball, Susan; Mesinkovska, Natasha A

Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials

巴瑞替尼治疗重度斑秃患者剂量递增的临床结果:BRAVE-AA1 和 BRAVE-AA2 试验的汇总分析

Ko, Justin M; Mayo, Tiffany T; Bergfeld, Wilma F; Dutronc, Yves; Yu, Guanglei; Ball, Susan G; Somani, Najwa; Craiglow, Brittany G

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

两项 III 期试验(BRAVE-AA1 和 BRAVE-AA2)中,巴瑞替尼治疗重度斑秃患者 52 周的疗效和安全性

Kwon, Ohsang; Senna, Maryanne M; Sinclair, Rodney; Ito, Taisuke; Dutronc, Yves; Lin, Chen-Yen; Yu, Guanglei; Chiasserini, Chiara; McCollam, Jill; Wu, Wen-Shuo; King, Brett

Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

巴瑞替尼治疗不同程度斑秃患者的疗效:BRAVE AA1 和 BRAVE AA2 研究的事后分析

Taylor, Susan; Korman, Neil J; Tsai, Tsen-Fang; Shimomura, Yutaka; Feely, Meghan; Dutronc, Yves; Wu, Wen-Shuo; Somani, Najwa; Tosti, Antonella

An Infected Arterial Aneurysm and a Dog Bite: Think at Capnocytophaga canimorsus!

感染性动脉瘤和狗咬伤:想想犬咬嗜二氧化碳菌!

Ducours, Maïlys; Leitao, Julie; Puges, Mathilde; Pereyre, Sabine; Gabriel, Frédéric; Dutronc, Hervé; Chevallier, Raphaelle; Pinaquy, Jean-Baptiste; Carcaud, Claire; Berard, Xavier; Cazanave, Charles

Development and validation of a new method for potential use of Psoriasis Area and Severity Index in teledermatology

开发和验证一种用于远程皮肤病学中银屑病面积和严重程度指数(PASI)潜在应用的新方法

Wu, Jason; Petto, Helmut; Dutronc, Yves; Burkhardt, Nicole; Gebauer, Kurt; Gooderham, Melinda

Development of the Scalp Hair Assessment PRO™ measure for alopecia areata

斑秃头皮毛发评估PRO™测量方法的开发

Wyrwich, K W; Kitchen, H; Knight, S; Aldhouse, N V J; Macey, J; Nunes, F P; Dutronc, Y; Mesinkovska, N; Ko, J M; King, B A

The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials

斑秃研究者总体评估量表:一种用于评估临床试验中具有临床意义的成功指标

Wyrwich, K W; Kitchen, H; Knight, S; Aldhouse, N V J; Macey, J; Nunes, F P; Dutronc, Y; Mesinkovska, N; Ko, J M; King, B A

Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata

斑秃患者眉毛、睫毛和指甲评估的临床医生报告结局 (ClinRO) 和患者报告结局 (PRO) 指标的开发

Wyrwich, Kathleen W; Kitchen, Helen; Knight, Sarah; Aldhouse, Natalie V J; Macey, Jake; Nunes, Fabio P; Dutronc, Yves; Mesinkovska, Natasha; Ko, Justin M; King, Brett A